Based on the Open Innovation system, HLB is growing into a global anti-cancer company based on various anti-cancer drugs obtained through a global network.
Under the medium-term vision of 'the Beginning of the Great Goal', we aim to market more than 5 anti-cancer drugs by 2025, by developing 'Rivoceranib', the best-in-class targeted anti-cancer therapy, and 'UNITE', the next-generation immunotherapy vaccine platform for cancer and allergies.
We will realize the dream of better life and life extension of humanity.
Company Details
- Employees
- 48
- Founded
- 1975
- Address
- 서울특별시 강남구 테헤란로 420 Kt 선릉타워 West 17층, 서울시,korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.hlb-group.com
- HQ
- 서울시
Hlb Group Questions
Hlb Group's website is http://www.hlb-group.com
Hlb Group's LinkedIn profile is https://kr.linkedin.com/company/hlb-group-korea
Hlb Group has
48 employees.
View email and phone details for 48
employees at Hlb Group.
Hlb Group's industry is
Pharmaceutical Manufacturing
Hlb Group's top competitors are
Dcamp,
Verismo Therapeutics,
Hlb Pharma Group,
Resilience Development Initiative (Rdi),
Voronoi Inc.,
Elevar Therapeutics,
Seegene Inc.,
Sam Chun Dang Pharm. Co. Ltd,
Regentree,
Hlb Life Science Medicare.
Hlb Group's categories are Pharmaceutical Manufacturing
Hlb Group's founding year is 1975
